Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
281-300 of 2,251 trials

Cholestatic Pruritus: Linerixibat Treatment Study

We are studying the long-term safety and tolerability of linerixibat for people with cholestatic pruritus due to primary biliary cholangitis. The trial also looks at how this treatment affects quality of life and itch relief.

Cholestatic PruritusPrimary Biliary Cholangitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Polycystic Ovary Syndrome: Letrozole vs. Gonadotropins for Insemination

We are studying whether letrozole can be a better option than gonadotropins for achieving pregnancy in women with polycystic ovary syndrome. The trial will also examine miscarriage rates and treatment responses.

Insemination in Patients with Polycystic Ovary Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

HER2-Positive Metastatic Cancer: Trastuzumab Emtansine Study

We are providing ongoing treatment with trastuzumab emtansine for patients who previously benefited from this therapy. The study aims to assess the safety of long-term use, either alone or with other cancer treatments.

Metastatic Breast CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Knee Cartilage Defects: Stem Cell Treatment Study

We are testing whether a combination of stem cells and a 3D scaffold improves healing in knee cartilage defects compared to standard treatment. This study also looks at the safety of using these stem cells.

Knee Cartilage Defect>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyRheumatology

Alpha-1 Antitrypsin Deficiency: Fazirsiran Treatment Study

We are investigating the long-term safety of fazirsiran for people with liver disease related to Alpha-1 Antitrypsin Deficiency. The study will also look at how this treatment affects liver health over time.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyPulmonology

Preventing Postoperative Pain in Children: Locoregional Analgesia Study

We are studying whether locoregional analgesia can help reduce long-term pain after orthopedic surgery in children. The trial compares pain levels and recovery outcomes between different pain management methods.

Postoperative Pain>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngology

Metastatic Non-Small Cell Lung Cancer: Pembrolizumab with Sacituzumab Govitecan

We are studying whether combining pembrolizumab with sacituzumab govitecan improves survival and quality of life for patients with metastatic non-small cell lung cancer. This trial compares the combination treatment to pembrolizumab alone.

Metastatic Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Pembrolizumab for Progressive Multifocal Leukoencephalopathy in Immunocompromised Patients

We are studying whether Pembrolizumab can help reduce the JCV viral load in the cerebrospinal fluid of immunocompromised patients with PML. This trial aims to understand its effects on neurological health and overall survival.

Progressive Multifocal Leukoencephalopathy (PML)6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesNeurology

Lung Cancer: Adagrasib Dosing Study

We are comparing two dosing schedules of adagrasib for patients with non-small cell lung cancer and a KRAS G12C mutation who have had previous treatments. The goal is to find out which regimen works better and is safer.

Non-small cell lung cancerEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Rare Ovarian Cancer: Abemaciclib and Letrozole Study

We are investigating the effects of a new treatment combining abemaciclib and letrozole for women with estrogen receptor positive rare ovarian cancer. The study aims to understand how well this treatment works and its impact on quality of life.

Adult-type Granulosa Cell TumorLow-Grade Serous Ovarian Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Non-Small Cell Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have a specific genetic mutation. This trial compares the effects of the combination treatment to chemotherapy alone.

Non-Small Cell Lung Cancer6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Staphylococcus aureus Bacteremia: SNAP Trial

We are testing various treatment options for patients with Staphylococcus aureus bacteremia to see how they impact survival and other health outcomes. This study aims to improve care for those affected by this serious infection.

Staphylococcus aureus Bacteremia3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Cardiogenic Shock: Early Empagliflozin Treatment

We are studying if starting empagliflozin early helps patients with cardiogenic shock improve their heart function and reduce hospital visits. This trial compares the new treatment with standard care to see which is more effective.

Cardiogenic Shock3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Metastatic Breast Cancer: Treatment Combinations Study

We are evaluating the effectiveness and safety of various treatment combinations for patients with metastatic breast cancer. This study aims to find better options for managing the disease.

Metastatic Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Gastroesophageal and Pancreatic Cancer: New Imaging Technique

We are testing a new PET/CT imaging method to see if it improves cancer diagnosis and staging for patients with gastroesophageal and pancreatic cancer. This study aims to enhance comfort and effectiveness compared to standard imaging.

Pancreatic and Gastroesophageal CancerEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Efepoetin Alfa for Anemia in Chronic Kidney Disease on Dialysis

We are studying whether efepoetin alfa can effectively manage anemia in patients with chronic kidney disease on dialysis, compared to another treatment. This trial will also assess safety and quality of life for participants.

Anemia of Chronic Disease1-2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyNephrology

Community-Acquired Pneumonia: Amoxicillin vs. Amoxicillin/Clavulanate

We are studying whether amoxicillin alone is as effective as amoxicillin/clavulanate for treating pneumonia in hospitalized patients aged 65 and older. This research may help determine the best antibiotic treatment for older adults.

Community-Acquired Pneumonia in Elderly Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Advanced Solid Tumors: BMS-986340 Treatment Study

We are testing a new treatment called BMS-986340, both alone and with other medications, for people with advanced solid tumors. The goal is to assess its safety and how well it may work against cancer.

Advanced Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Advanced Cholangiocarcinoma: Futibatinib Study

We are studying the effects of futibatinib in patients with advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. The goal is to see if it helps improve their condition and to understand its safety.

Cholangiocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Progressive Pulmonary Fibrosis: FAPI-PET Imaging Study

We are exploring if a special imaging method can help identify the type of lung condition in patients with progressive pulmonary fibrosis. This may improve how we understand and treat their disease.

Progressive Pulmonary Fibrosis3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPulmonology